**IntroductIon**

With the increasing incidence of inflammatory bowel diseases, Crohn’s disease (CD) has become one of the most challenging diseases in gastroenterology both in terms of diagnosis and treatment. Therefore, it is essential to use objective methods to estimate the disease activity and its progression or regression over time.

**OBJECTIVES**

The aim of the study was to construct a simple scale for assessing the activity of CD (Simple Enterographic Activity Score for Crohn’s Disease – SEAS-CD) in MRE and to investigate its clinical usefulness.

**PATIENTS AND METHODS**

We conducted a retrospective analysis of MRE findings in 122 patients with CD. Disease activity was assessed using the SEAS-CD. The reference standard was endoscopic assessment using the Simple Endoscopic Score for Crohn’s Disease (SES-CD). We assessed correlations between SEAS-CD and endoscopic, clinical, and biochemical findings. We also proposed the Global Crohn’s Disease Activity Score to assess total CD activity by summarizing the colonic SES-CD and SEAS-CD scores.

**RESULTS**

In the validation group (n = 62), a significant correlation between the ileal SES-CD and ileal SEAS-CD scores was noted ($r = 0.72, P <0.0001$). In patients with isolated small-bowel CD, there was a significant correlation between SEAS-CD and Crohn’s Disease Activity Index (CDAI), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), hemoglobin (Hb), albumin, and platelet count. In patients with ileocolonic CD, the Global Crohn’s Disease Activity Score correlated with CDAI, CRP, ESR, Hb, and hematocrit.

**CONCLUSIONS**

SEAS-CD is a useful tool for the quantification of small-bowel CD activity assessed by MRE. The Global Crohn’s Disease Activity Score may be useful in assessing the progression of lesions in patients with ileocolonic CD.

---

**KEY WORDS**

ileocolonoscopy, inflammatory bowel disease, magnetic resonance enterography

**ABSTRACT**

Magnetic resonance enterography (MRE) is believed to be a reliable diagnostic method in assessing the activity of small-bowel Crohn’s disease (CD). However, there are no scales for quantifying MRE scores that could be used in everyday clinical practice.

The aim of the study was to construct a simple scale for assessing the activity of CD (Simple Enterographic Activity Score for Crohn’s Disease – SEAS-CD) in MRE and to investigate its clinical usefulness.

We conducted a retrospective analysis of MRE findings in 122 patients with CD. Disease activity was assessed using the SEAS-CD. The reference standard was endoscopic assessment using the Simple Endoscopic Score for Crohn’s Disease (SES-CD). We assessed correlations between SEAS-CD and endoscopic, clinical, and biochemical findings. We also proposed the Global Crohn’s Disease Activity Score to assess total CD activity by summarizing the colonic SES-CD and SEAS-CD scores.

In the validation group (n = 62), a significant correlation between the ileal SES-CD and ileal SEAS-CD scores was noted ($r = 0.72, P <0.0001$). In patients with isolated small-bowel CD, there was a significant correlation between SEAS-CD and Crohn’s Disease Activity Index (CDAI), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), hemoglobin (Hb), albumin, and platelet count. In patients with ileocolonic CD, the Global Crohn’s Disease Activity Score correlated with CDAI, CRP, ESR, Hb, and hematocrit.

SEAS-CD is a useful tool for the quantification of small-bowel CD activity assessed by MRE. The Global Crohn’s Disease Activity Score may be useful in assessing the progression of lesions in patients with ileocolonic CD.
TABLE 1 Simple Enterographic Activity Score for Crohn’s Disease

| MRE feature                          | Grading scale                                   |
|--------------------------------------|-------------------------------------------------|
| bowel thickening                     | <3 mm: 0 pts                                   |
|                                      | 3–7 mm: 1 pt                                   |
| contrast enhancement                 | none: 0 pts                                    |
| fat wrapping                         | none: 0 pts                                    |
| proliferation of mesenteric vasculature | none: 0 pts                                    |
| mesenteric lymphadenopathy           | none: 0 pts                                    |
| stenotic complications               | none: 0 pts                                    |
| intra-abdominal fistulas              | none: 0 pts                                    |
| extent of the disease in jejunum or ileum | <30 mm: 1 pt                                  |
|                                      | 30–1500 mm: 2 pts                              |
|                                      | >1500 mm: 3 pts                                |
| Abbreviations: MRE – magnetic resonance enterography

| Grade                                                                 |
|-----------------------------------------------------------------------|
| bowel thickening                                                      |
| <3 mm: 0 pts                                                          |
| 3–7 mm: 1 pt                                                          |
| >7 mm: 2 pts                                                          |
| contrast enhancement                                                  |
| none: 0 pts                                                           |
| present: 1 pt                                                         |
| fat wrapping                                                          |
| none: 0 pts                                                           |
| present: 1 pt                                                         |
| plication of mesenteric vasculature                                   |
| none: 0 pts                                                           |
| <5 vessels/3 cm² of mesenteric fat: 1 pt                               |
| ≥5 vessels/3 cm² of mesenteric fat: 2 pts                              |
| mesenteric lymphadenopathy                                             |
| none: 0 pts                                                           |
| <10 enlarged lymph nodes: 1 pt                                        |
| ≥10 enlarged lymph nodes: 2 pts                                       |
| ulcerations                                                           |
| none: 0 pts                                                           |
| at least 1 ulceration present, not exceeding ½ of bowel thickness: 1 pt |
| at least 1 ulceration present, exceeding half of bowel thickness: 2 pts |
| stenotic complications                                                |
| none: 0 pts                                                           |
| stenosis without prestenotic dilatation: 1 pt                         |
| at least 1 stenosis with prestenotic dilatation: 2 pts                |
| intra-abdominal fistulas                                               |
| none: 0 pts                                                           |
| at least 1 intra-abdominal fistula present: 5 pts                     |

crucial for the assessment of the global extent of CD and its activity. Magnetic resonance enterography (MRE) allows to visualize the whole intestinal wall and the extra-enteric inflammatory involvement. Because MRE is radiation-free, it has been regarded as the method of choice in the radiologic examination of the small bowel.6,7

One of the most important limitations of MRE is the lack of objective scales that enable the quantitative assessment of CD activity and comparison of different MRE modalities. In this study, we designed a scale called the Simple Enterographic Activity Score for Crohn’s Disease (SEAS-CD) for the assessment of CD activity in the small bowel. We compared the results of this scale with those of endoscopic assessment of CD activity in the ileum, which we considered as the reference standard. To estimate the global CD activity, we combined the 2 most accurate techniques for the detection of inflammatory activity in the small and large bowels (MRE and colonoscopy, respectively) and calculated the Global Crohn’s Disease Activity Score. We then correlated it with clinical and biochemical findings. The novelty of our study is that the proposed SEAS-CD scale allows to assess CD activity objectively, and because of its simplicity, it can be easily applied in everyday practice, unlike the other available indices.

PATIENTS AND METHODS Patients We conducted a retrospective analysis of the MRE findings in 122 patients with CD. All patients were hospitalized at the Heliodor Święcicki University Hospital in Poznań, Poland, because of CD exacerbation or to undergo follow-up examinations during the remission period. Clinical activity of the disease was assessed using the CD Activity Index (CDAI) and blood inflammatory markers were measured.

Magnetic resonance enterography In each patient, MRE was performed using the same study protocol. Patients fasted for 6 hours before MRE and 1500 ml of oral polyethylene glycol was administered 30 minutes before the procedure. Fifteen minutes before the scanning, 4 mg of buscolysin was injected intravenously to reduce bowel motility. To reduce respiratory movements and provide higher image quality, the imaging was performed under breath-hold conditions. The standard study protocol consisted of the following sequences: 1) fast imaging with steady-state free precession (TrueFISP) sequences in the coronal and transverse planes for anatomic overview and for bowel dilatation or wall-thickening detection 2) single-shot turbo spin-echo (HASTE) sequences with fat suppression in the coronal plane to assess fluid and edema of the bowel and surrounding tissues 3) cine loop coronal images for the visualization of the bowel movements and stenosis 4) volumetric interpolated breath hold examination (VIBE) T1-weighted 3D Fast Low Angle Shot (FLASH) technique with fat selective pre-pulse before and after intravenous injection of gadolinium contrast (dose of 0.1 mmol/kg followed by 20 ml of saline) for the detection of inflammatory process.

All MRE examinations were assessed by one radiologist with over 10 years of experience in this type of imaging technique. The SEAS-CD scale was designed on the basis of a thorough analysis of the previously developed scales and available literature data on MRE imaging in CD.8-14 We identified the most important features reflecting CD activity: bowel thickening, contrast enhancement, edema of the perivisceral fatty tissue with or without vascular proliferation, enlargement of the mesenteric lymph nodes, presence of mucosal ulcerations, bowel strictures and presence of enterointeretic fistulas, and disease extent.10 Depending on the presence and characteristics of each feature, an adequate score was calculated according to the proposed scale (TABLE 1). Enterographic activity was assessed separately for the jejunum and ileum (jejunal SEAS-CD and ileal SEAS-CD) and then summarized to obtain the total SEAS-CD.

Ileocolonoscopy Ileocolonoscopy was performed in 72 of 122 patients (59%) by an experienced...
All statistical analyses were performed using the GraphPad Prism version 4.0 software. The Spearman coefficients were calculated to assess the correlations between SEAS-CD, SES-CD, CDAI, and biochemical markers. A $P$-value of less than 0.05 was considered statistically significant.

Ethical considerations
An informed consent approved by the Institutional Review Board at the Heliodor Święcicki University Hospital was obtained from each participant before entering the study.

RESULTS
Characteristics of the study population
The clinical, epidemiological, and biochemical characteristics of the patient population are summarized in Table 3.

The ileum was the most frequently involved bowel segment in the whole study group (121 of 122 patients; 99%). In the majority of cases (77 of 121 patients; 64%), CD involved the distal loop (distal 15 cm) of the ileum. In 44 of 121 patients (36%), the ileal involvement was greater than 15 cm.

Validation group
A significant correlation between the ileal SES-CD and ileal SEAS-CD was observed in the validation group (Figure 2). However, neither the ileal SEAS-CD nor total SEAS-CD correlated with the CDAI or blood inflammatory markers. A strong positive correlation was found only between the total SEAS-CD and platelet count ($r = 0.3, P = 0.02$).

In a separate analysis of variables composing SEAS-CD, we observed the strongest correlation between bowel thickening ($r = 0.4, P = 0.01$), mesenteric lymphadenopathy ($r = 0.4, P = 0.003$), and disease extent ($r = 0.6, P < 0.0001$) with the ileal SES-CD.

Patients with isolated small-bowel Crohn’s disease
We observed significant correlations between both the total SEAS-CD and ileal SEAS-CD and CDAI. The SEAS-CD also correlated significantly with the majority of blood inflammatory markers (Table 4).

Patients with ileocolonic Crohn’s disease
In this group, the total SEAS-CD did not correlate with the CDAI or the majority of blood inflammatory markers. The Global Crohn’s Disease Activity Score significantly correlated with SEAS-CD and

### Table 2: Simple Endoscopic Score for Crohn’s Disease (SES-CD)\(^{16}\)

| Presence and size of ulcers | Extent of ulcerated surface | Extent of affected surface | Presence and type of narrowings |
|----------------------------|-----------------------------|---------------------------|--------------------------------|
| none: 0 pts                | 0%: 0 pts                   | 0%: 0 pts                 | none: 0 pts                    |
| aphthous, <0.5 cm: 1 pt    | <10%; 1 pt                  | <50%; 1 pts               | single, can be passed: 1 pt    |
| large, 0.5–2 cm: 2 pts     | 10%–30%; 2 pts              | 50%–75%; 2 pts            | multiple, can be passed: 2 pts  |
| large, >2 cm: 3 pts        | >30%; 3 pts                 | >75%; 3 pts               | cannot be passed: 3 pts        |

* each variable is calculated separately in the ileum (ileal SES-CD) and the right colon, transverse colon, left colon, and rectum (colonic SES-CD)
Simple Enterographic Activity Score for Crohn’s Disease...

Enteroscopy and capsule endoscopy are considered the gold standard in the assessment of the extent and activity of small-bowel CD. However, these methods are not widely available, and they are time-consuming, expensive, and invasive. Therefore, cross-sectional imaging techniques such as MRE are increasingly applied in CD.

So far, several MRE indices have been developed for the assessment of CD activity. One of the most advanced indices, in terms of methodology, is the Magnetic Resonance Index of Activity (MaRIA) proposed by Rimola et al. In this model, a mathematical formula is used that includes the most accurate predictors of active disease, as compared with endoscopic findings. These predictors are as follows: wall thickness, relative contrast enhancement, and the presence of edema and ulcers. The authors concluded that MaRIA correlated with the endoscopic activity of CD. However, the magnetic resonance technique applied in this study differed from the majority of MRE protocols. To assess the MRE activity of CD in the large bowel, the colon was additionally filled with warm water by inserting a flexible rectal balloon catheter. This gave sufficient bowel distension and allowed to assess the correlation between the MRE and endoscopic findings in the colon.

Several other indices have also been proposed; however, because of significant differences between MRE protocols, complexity of the MRE scores, and different types of study group definitions, those indices are rarely implemented in everyday practice. Therefore, we designed a simple score that includes the most commonly assessed variables.

Wall thickening with enhancement after intravenous contrast administration is considered to be one of the crucial signs of active SES-CD as well as with the CDAI and the major blood inflammatory markers (TABLE 6).

**DISCUSSION**

**TABLE 3** Characteristics of the study population (n = 122)

| Feature                        | Result                                      |
|--------------------------------|---------------------------------------------|
| sex, male/female, %            | 62/60 (51/49)                               |
| age, y                         | 33 ±12                                      |
| disease duration, y            | 5 ±4                                        |
| disease behavior, n (%)        | inflammatory 115 (94)                      |
|                                | penetrating 39 (32)                         |
|                                | stricturing 18 (15)                         |
| disease location, n (%)        | colon 58 (47)                               |
|                                | ileum 121 (99)                              |
|                                | jejunum 9 (7)                               |
| previous surgery, n (%)        | 31 (25)                                     |
| CDAI                           | 250 (207–260)                               |
| SES-CD                         | 11 (10–14)                                  |
| ileal SES-CD                   | 5 (4–6)                                     |
| colonic SES-CD                 | 6 (6–10)                                    |
| total SES-CD                   | 11 (10–12)                                  |
| ileal SEAS-CD                  | 11 (9–11)                                   |
| jejunal SEAS-CD                | 0 (0–1)                                     |
| Global Crohn’s Disease Activity Score | 17 (15–20)                               |
| CRP, mg/l                      | 22.9 ±26                                    |
| ESR, mm/h                      | 31 ±22                                      |
| RBC, 10⁷/mm³                   | 4.4 ±0.7                                    |
| Hb, g/dl                       | 12.3 ±2.1                                   |
| Ht (%)                         | 37 ±5                                       |
| PLT, 10⁹/l                     | 367 ±117                                    |
| WBC, 10³/mm³                   | 7.74 ±3.5                                   |
| fibrinogen, mg/dl              | 463 ±152                                    |
| total protein, g/dl            | 6.8 ±0.8                                    |
| albumin, g/dl                  | 4 ±0.7                                      |

Data are presented as mean ± standard deviation, median (95% confidence interval), or number (percentage).

Abbreviations: CD – Crohn’s disease, CDAI – Crohn’s Disease Activity Index, CRP – C-reactive protein, ESR – erythrocyte sedimentation rate, GI – gastrointestinal tract, Hb – hemoglobin, Ht – hematocrit, PLT – platelet count, RBC – red blood count, SEAS-CD – Simple Enterographic Activity Score for Crohn’s Disease, SES-CD – Simple Endoscopic Score for Crohn’s Disease, WBC – white blood count

**FIGURE 2** Correlation between the ileal Simple Enterographic Activity Score for Crohn’s Disease (SEAS-CD) and ileal Simple Endoscopic Score for Crohn’s Disease (SES-CD) in the validation group

$r = 0.7127, P < 0.0001$
inflammation in the gastrointestinal tract. Rimola et al. demonstrated that these variables were among the most accurate predictors of an active CD when compared with endoscopy. On the other hand, it is also known that the enhancement pattern can be predictive of active bowel inflammation. A hyperintense signal in the mucosa and serosa, in contrast to the hypointense signal from submucosal edema and the muscle layer, gives a characteristic layered appearance on T1-weighted fat suppressed sequence. The fibrotic transformation of the gut wall is often characterized by a more homogenous enhancement pattern after contrast administration. The presence and the size of ulcers are also known to be one of the most sensitive imaging features of active CD. MRE is also an accurate tool for the detection of bowel stenosis, which is believed to be a consequence of an active disease either due to inflammatory edema of the gut wall or fibrotic destruction. Moreover, a prestenotic dilatation of the gut reflects the intensity of stenotic complication, being a structural consequence of gut wall narrowing. Another phenomenon strongly associated with inflammatory CD activity is a fibrofatty proliferation (fat wrapping or “creeping fat”) of the mesentery around the inflamed bowel segment. This is very often accompanied by the engorgement of the mesenteric vessels supplying the inflamed bowel loop (comb sign). Also, the enlargement and contrast enhancement of the mesenteric lymph nodes assessed mainly on T1-weighted sequences is believed to be a sensitive MRE symptom of an active CD. Complications such as enterointeretic, enterovesical, and enterocutaneous fistulas reflecting the extensive destruction of the digestive tract in CD can also be detected by MRE. However, it should be mentioned that according to the more recent data, a dynamic assessment of CD activity in MRE might be superior to a static evaluation.

To evaluate the usefulness of the proposed SEAS-CD, we first compared it with the score assessing the endoscopic activity in the same disease location. This was our gold standard, because the ileum is the only part of the small bowel that can be assessed both by routine ileocolonoscopy and by MRE. In the validation group, we demonstrated a significant correlation between the ileal SEAS-CD and ileal SES-CD. This finding shows that our score is reliable in the evaluation of CD activity, and it provides the basis for the hypothesis that this correlation would also be strong in the jejunum. Moreover, a subanalysis revealed that disease extent, mesenteric lymphadenopathy, and bowel thickening assessed by MRE were the strongest predictors of active ileal disease. Interestingly, among other biochemical markers, we only found a correlation between the SEAS-CD and platelet count. However, it is well known that functional and structural disturbances of the platelet count are observed in inflammatory bowel diseases, and that it is a sensitive parameter reflecting CD activity. The lack of correlation of the total and ileal SEAS-CD with the total SES-CD, CDAI, as well as with other biochemical parameters was to be expected, considering that some of the patients in this group also had colonic CD. This fact affects the SES-CD, CDAI, and blood inflammatory markers, but obviously does not affect the SEAS-CD score.

To eliminate this effect and to perform a reliable comparison between the clinical and laboratory data with our MRE score, we analyzed only patients with small-bowel CD. A significant correlation was then noted between the SEAS-CD and platelet count. However, it is well known that functional and structural disturbances of the platelet count are observed in inflammatory bowel diseases, and that it is a sensitive parameter reflecting CD activity. The lack of correlation of the total and ileal SEAS-CD with the total SES-CD, CDAI, as well as with other biochemical parameters was to be expected, considering that some of the patients in this group also had colonic CD. This fact affects the SES-CD, CDAI, and blood inflammatory markers, but obviously does not affect the SEAS-CD score.

Another question is whether MRE allows to differentiate an inflammatory pattern of CD from its inactive form. In our study, the SEAS-CD did not allow to differentiate between the 2 groups defined as inactive or active by C-reactive protein (CRP) concentration (data not shown). However, it is questionable whether there is a perfect marker reflecting the disease behavior in CD. The only reliable method in the assessment of CD pattern is a direct intraoperative visualization together with histological examination. This was investigated by Schill et al. who showed that MRE is an excellent tool for precise estimation of different CD patterns. Interestingly, we also observed a significant inverse correlation between the SEAS-CD and blood albumin levels. In this case, hypoalbuminemia could be caused...
during colonoscopy; hence, this investigation is considered a first-choice diagnostic procedure in the case of colonic CD. Considering that the ileo-colonic location of inflammatory lesions in CD is most common, it is essential to perform both investigations, endoscopy and MRE, in everyday clinical practice to be able to fully assess the extent and activity of CD.

However, the question remains of whether it is possible to quantify the total activity of CD, including inflammatory lesions in the small and large intestines. As we confirmed in this study, the proposed SEAS-CD is useful in the estimation of small-bowel CD activity. Undoubtedly, the SES-CD remains a useful objective tool for the assessment of endoscopic colonic CD severity. This was the reason why we constructed the Global Crohn’s Disease Activity Score by summarizing the total SEAS-CD and colonic SES-CD. A statistical analysis revealed that the Global Crohn’s Disease Activity Score correlated with the CDAI and with the majority of the biochemical markers. In our opinion, the use of this score could improve and optimize objective monitoring of patients with CD, primarily those treated with immunosuppressants or biological agents. In both

As shown above, the SEAS-CD allows for the objective assessment of the inflammatory activity of small-bowel CD. It is especially important in the assessment of the effectiveness of various treatments, because the CDAI and CRP reflect CD activity only subjectively (CDAI) or only indirectly (CRP). However, it must be emphasized that a large proportion of patients also have colonic location of CD. In this group of patients, classical MRE examination is not a useful diagnostic tool for the assessment of colonic inflammatory activity because of insufficient large bowel distension in the majority of the cases. However, MRE still remains a useful cross-sectional imaging technique, first of all, in the evaluation of small bowel inflammatory lesions in CD. On the other hand, the intubation of the ileum is not always technically possible during colonoscopy; hence, this investigation is considered a first-choice diagnostic procedure in the case of colonic CD. Considering that the ileocolonic location of inflammatory lesions in CD is most common, it is essential to perform both investigations, endoscopy and MRE, in everyday clinical practice to be able to fully assess the extent and activity of CD.

However, the question remains of whether it is possible to quantify the total activity of CD, including inflammatory lesions in the small and large intestines. As we confirmed in this study, the proposed SEAS-CD is useful in the estimation of small-bowel CD activity. Undoubtedly, the SES-CD remains a useful objective tool for the assessment of endoscopic colonic CD severity. This was the reason why we constructed the Global Crohn’s Disease Activity Score by summarizing the total SEAS-CD and colonic SES-CD. A statistical analysis revealed that the Global Crohn’s Disease Activity Score correlated with the CDAI and with the majority of the biochemical markers. In our opinion, the use of this score could improve and optimize objective monitoring of patients with CD, primarily those treated with immunosuppressants or biological agents. In both

### Table 5

| Total SEAS-CD | Ileal SEAS-CD | SES-CD | Global CD Activity Score |
|---------------|---------------|--------|--------------------------|
| none          | $r = 0.9$     | NS     | $r = 0.72$               |
| $P < 0.0001$  |               |        | $P < 0.0001$             |
| Ileal SEAS-CD | none          | NS     | $r = 0.72$               |
| $r = 0.9$     |               |        | $P = 0.003$              |
| $P < 0.0001$  |               |        | $P = 0.003$              |
| SES-CD        | none          | NS     | $r = 0.72$               |
| $r = 0.72$    |               |        | $P < 0.0001$             |
| Global CD Activity Score | $r = 0.37$ | $r = 0.37$ | $r = 0.37$ |
| $P = 0.003$  | $P = 0.003$  | $P = 0.001$ | $P = 0.01$ |
| CDAI          | NS            | NS     | $r = 0.37$               |
| $r = 0.37$    |               |        | $P = 0.008$              |
| $P < 0.0001$  |               |        | $P = 0.003$              |
| CRP           | NS            | NS     | $r = 0.39$               |
| $r = 0.39$    |               |        | $P = 0.001$              |
| $P < 0.0001$  |               |        | $P = 0.01$               |
| ESR           | NS            | NS     | $r = 0.39$               |
| $r = 0.39$    |               |        | $P = 0.001$              |
| $P < 0.0001$  |               |        | $P = 0.01$               |
| RBC           | NS            | NS     | NS                       |
| NS            |               |        | NS                       |
| Hb            | $r = -0.18$   | NS     | $r = -0.39$              |
| $P = 0.07$    |               |        | $P = 0.001$              |
| Ht            | $r = -0.2$    | NS     | $r = -0.3$               |
| $P = 0.06$    |               |        | $P = 0.02$               |
| WBC           | NS            | NS     | NS                       |
| NS            |               |        | NS                       |
| PLT           | $r = 0.24$    | NS     | $r = 0.24$               |
| $P = 0.01$    |               |        | $P = 0.06$               |
| fibrinogen    | NS            | NS     | NS                       |
| $r = 0.36$    |               |        | NS                       |
| $P = 0.009$   |               |        | NS                       |
| total protein | NS            | NS     | NS                       |
| $r = -0.2$    |               |        | NS                       |
| $P = 0.06$    |               |        | NS                       |
| albumin       | $r = -0.18$   | NS     | NS                       |
| $P = 0.06$    |               |        | NS                       |

Abbreviations: see TABLES 3 and 4
treatment options, a dynamic and quantified assessment of the disease progression or regression is crucial to make proper decisions as to whether to continue, discontinue, or change the therapy.

Our study has several limitations. First of all, our analysis was retrospective. A prospective study would be essential to validate the usefulness of the SEAS-CD, especially in comparison with endoscopy. However, in our opinion, the results of this study are convincing enough to hypothesize that SEAS-CD reliably reflects CD severity. Finally, the MRE results were assessed only by 1 examiner; thus, there was no evaluation of interobserver agreement. However, other studies have shown that this agreement is high, especially in large university radiological centers. We would also like to emphasize that our radiologist is highly experienced in this type of MRE technique.

In conclusion, we believe that the simplicity of the SEAS-CD will encourage its wider use in everyday clinical practice. This, in turn, could improve the quality of care in patients with CD, especially in those treated with drugs that have the potential of healing the gut, such as immunosuppressive and biological agents.

REFERENCES

1. Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011; 140: 1785-1794.

2. Best WR, Beckett JM, Singletary JW, Kern F Jr. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976; 70: 439-444.

3. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006; 55: 426-431.

4. Szczepanski K, Owczerak D, Pyrkko-Polockczyk, et al. Proinflammatory cytokines in the saliva of patients with active and non-active Crohn’s disease. Pol Arch Med Wewn. 2012; 5: 200-208.

5. Owczerak D, Cibor D, Glowacki MK, et al. TNF-α and soluble forms of TNF receptors 1 and 2 in the serum of patients with Crohn’s disease and ulcerative colitis. Pol Arch Med Wewn. 2012; 12: 616-623.

6. Reenaers C, Belaiche J, Louis E. Impact of medical therapies on inflammatory bowel disease complication rate. World J Gastroenterol. 2012; 18: 3823-3827.

7. Travis S, Fagian BG, Rutgeerts P, van Deventer S. The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy. J Crohns Colitis. 2012; 6 (Suppl 2): S250-S259.

8. Masselli G, Gualdi G. MR imaging of the small bowel. Radiology. 2012; 264: 333-348.

9. Kayahan A, Dommern J, Dahi F, Oto A. Magnetic resonance enterography in Crohn’s disease: standard and advanced techniques. World J Radiol. 2010; 2: 113-121.

10. Colombel JF, Solem CA, Sandborn WJ, et al. Quantitative measurement and visual assessment of ileal Crohn’s disease activity by computed tomography enterography: correlation with endoscopic severity and C-reactive protein. Gut. 2006; 55: 1561-1567.

11. Fiorino G, Bonfaccio C, Peyrin-Biroulet L, et al. Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn’s disease. Inflamm Bowel Dis. 2011; 17: 1073-1080.

12. Hyun SB, Kitaura Y, Nagahori M, et al. Magnetic resonance enterocolonography is useful for simultaneous evaluation of the small and large intestinal lesions in Crohn’s disease. Inflamm Bowel Dis. 2011; 17: 1063-1072.

13. Rimola J, Ordis I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn’s disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis. 2011; 17: 1759-1768.

14. Gallego Ojea JC, Echarri Pludo AI, Porta Vila A. [Crohn’s disease: the usefulness of MR enterography in the detection of recurrence after surgery]. Radiología. 2011; 53: 552-559. Spanish.

15. Amitai MM, Ben-Horin S, Elakir M, Koplov U. Magnetic resonance enterography in Crohn’s disease: A guide to common imaging manifestations for the IBD physician. J Crohns Colitis. 2012 Oct 31. [Epub ahead of print].

16. Daperno M, O’Heaens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004; 60: 506-512.

17. Cullen G, Donnellan F, Boherty GA, et al. Evaluation of the small bowel in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2013; 7: 239-251.

18. Pariente B, Cosnes J, Danese S, et al. Development of the Crohn’s disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011; 17: 1415-1422.

19. Rimola J, Rodriguez S, Garcia-Bosch O, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn’s disease. Gut. 2009; 58: 1113-1120.

20. Punwani S, Rodriguez-Justo M, Bainbridge A, et al. Mural inflammation in Crohn disease: location-matched histologic validation of MR imaging features. Radiology. 2009; 252: 712-720.

21. Forrassa F, Brenasuti C, Bensazita L. Role of magnetic resonance enterography in differentiating between fibrotic and active inflammatory small bowel stenosis in patients with Crohn’s disease. J Clin Imaging Sci. 2011; 1: 35.

22. Gourtsoyianni S, Papanikolaou N, Amanakis E, et al. Crohn’s disease lymphadenopathy: MR imaging findings. Eur J Radiol. 2009; 69: 425-428.

23. Collmann JL, Bickelhaupt F, Froshlich JM, et al. MR imaging in Crohn’s disease: correlation of MR motility measurement with histopathology in the terminal ileum. Neurogastroenterol Motil. 2013 Jun 7. [Epub ahead of print].

24. Danese S, Motte Cd Cde L, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol. 2004; 99: 938-945.

25. Schill G, Lesalineks I, Haimet M, et al. Assessment of disease behavior in patients with Crohn’s disease by MR enterography. Inflamm Bowel Dis. 2013; 19: 983-990.
ARTYKUŁ ORYGINALNY

Prosta skala aktywności choroby Leśniowskiego-Crohna w enterografii – porównanie z wynikami badań endoskopowych, biochemicznych i z aktywnością kliniczną choroby

Piotr Eder¹, Katarzyna Katulska², Liliana Łykowska-Szuber¹, Kamila Stawczyk-Eder¹, Iwona Krela-Każmierczak¹, Krzysztof Linke¹

¹ Katedra i Klinika Gastroenterologii, Żywnienia Człowieka i Chorób Wewnętrznych, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Poznań
² Katedra i Zakład Radiologii, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Poznań

Adres do korespondencji:
dr med. Piotr Eder, Katedra i Klinika Gastroenterologii, Żywnienia Człowieka i Chorób Wewnętrznych, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, ul. Przybyszewskiego 49, 60-355 Poznań, tel.: 61-869-13-43, fax: 61-869-16-86, e-mail: piotr.eder@op.pl

Praca wpłynęła: 23.03.2013.
Przyjęta do druku: 13.06.2013.
Publikacja online: 14.06.2013.
Nie zgłoszono sprzeczności interesów.

SŁOWA KLUCZOWE
enterografia
rezonansu magnetycznego,
iloekolonoskopia,
nieswoiste zapalenia jelit

STRESZCZENIE

Wprowadzenie EnteroGRAFIA rezonansu magnetycznego (magnetic resonance enterography – MRE) jest uważana za wiarygodne badanie do oceny aktywności choroby Leśniowskiego-Crohna (ChLC) w jelice cienkim. Brakuje jednak skal służących obiektywizacji wyników MRE, które mogłyby znaleźć zastosowanie w codziennej praktyce lekarskiej.

Celem badania było skonstruowanie i ocena przydatności klinicznej prostej skali oceniającej aktywność ChLC w MRE (Simple Enterographic Activity Score for Crohn’s Disease – SEAS-CD).

Pacjenci i Metody

Dokonano retrospektywnej analizy wyników badań MRE wśród 122 pacjentów z ChLC. Aktywność choroby w MRE oceniano za pomocą skali SEAS-CD. Punkt odniesienia była ocena endoskopowa według skali Simple Endoscopic Score for Crohn’s Disease (SES-CD). Badano korelacje między SEAS-CD a wynikami badań endoskopowych, klinicznych i biochemicznych. Zaproponowano także skalę do oceny całkowitej aktywności ChLC (Global Crohn’s Disease Activity Score) poprzez zsumowanie wyników SEAS-CD i SES-CD obliczonych w zakresie jelita grubego.

Wyniki

W grupie walidacyjnej (n = 62) wykazano korelację między aktywnością ChLC w jelice krętym ocenianą równolegle za pomocą skali SES-CD oraz SEAS-CD (r = 0,72; p < 0,0001). U chorych z lokalizacją zmian w jelicie cienkim wykazano istotną korelację SEAS-CD z: indeksem aktywności klinicznej ChLC (Crohn’s Disease Activity Index – CDAI), stężeniem białka C-reaktywnego (C-reactive protein – CRP), odczynem Biernackiego (OB), stężeniem hemoglobiny (Hb), liczbą płytek krwi oraz stężeniem albuminy. W przypadku zmian zarówno w jelicie cienkim i grubym, całkowita aktywność ChLC korelowała z CDAI, CRP, OB, Hb i hematokrytem.

Wnioski

SEAS-CD jest przydatnym narzędziem do oceny ilościowej aktywności ChLC w jelice cienkim dokonanej za pomocą MRE. Ocena całkowitej aktywności ChLC może być pomocna w ocenie nasilenia zmian chorobowych u pacjentów z zajęciem jelita cienkiego i grubego.